Fukuda Denshi (6960) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
9 Sep, 2025Executive summary
Net sales for the third quarter reached ¥99,395 million, a 0.1% increase year-over-year.
Operating profit declined 9.8% year-over-year to ¥17,392 million.
Ordinary profit was ¥17,990 million, down 8.2% year-over-year.
Profit attributable to owners of parent fell 9.3% year-over-year to ¥12,374 million.
Comprehensive income decreased 27.5% year-over-year to ¥11,365 million.
Financial highlights
Earnings per share for the quarter were ¥429.25, compared to ¥450.77 a year earlier.
Shareholders’ equity ratio improved to 83.5% from 80.8% at the end of the previous fiscal year.
Net assets increased to ¥174,856 million, up ¥5,847 million from March 2024.
Cash and deposits rose by ¥5,753 million to ¥65,975 million.
Total assets were ¥209,429 million, up ¥364 million from the previous fiscal year.
Outlook and guidance
Full-year net sales forecast is ¥135,000 million, up 3.8% year-over-year.
Operating profit for the full year is projected at ¥23,000 million, up 13.2% year-over-year.
Ordinary profit forecasted at ¥23,000 million, up 14.8% year-over-year.
Profit attributable to owners of parent expected to reach ¥16,500 million, up 11.7% year-over-year.
No change in the previously announced full-year forecast due to steady third-quarter sales.
Latest events from Fukuda Denshi
- Slight YoY profit decline offset by strong comprehensive income and stable full-year outlook.6960
Q3 20265 Feb 2026 - Net sales up 0.8% and operating profit steady, with segment shifts and stable full-year outlook.6960
Q2 202612 Nov 2025 - Sales rose 4% year-over-year, but profits declined; full-year guidance and dividends unchanged.6960
Q1 20259 Sep 2025 - First-half profits fell on lower sales, but full-year guidance and dividend plans remain unchanged.6960
Q2 20259 Sep 2025 - Slight declines in sales and profit, with FY2026 guidance indicating further contraction.6960
Q4 20259 Sep 2025 - Profits declined despite stable sales; medical treatment and consumables segments showed growth.6960
Q1 20269 Sep 2025